T he occurrence of sudden cardiac death in asymptomatic children is a rare but feared event. Ventricular pre-excitation (referred to as Wolff-Parkinson-White syndrome when associated with symptoms of supraventricular tachycardia) is one of the underlying causes of such events, with the mechanism of sudden death attributed to rapid antegrade conduction of atrial tachycardias via the accessory pathway resulting in ventricular fibrillation. Although estimates of the lifetime risk of mortality secondary to this ECG pattern vary somewhat, most suggest this risk to be in the range of 1:1000 pts/yr. [1] [2] [3] Patient factors suggested to be associated with an increased risk for sudden cardiac death include inducibility of tachycardia, male sex, presence of multiple accessory pathways and, most importantly, the capacity of the accessory pathway to perform rapidly. 1, [3] [4] [5] Most patients whose initial presentation was a life-threatening event have an accessory pathway capable of conducting at cycle lengths faster than 220 to 250 ms. 1, 3, 6, 7 
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It is disconcerting that studies have identified previously asymptomatic children with ventricular pre-excitation whose initial and only symptom was ventricular fibrillation. 1, 6, 8 Although it would seem reasonable to assume that patients with symptoms of tachycardia were somehow at higher risk for these potentially lethal complications, the risk profiles of symptomatic and asymptomatic patients may in fact be similar. 9 Asymptomatic patients in the past have been incidentally discovered, but increasingly they are identified as a result of ECG screening before sports participation or medication prescription. It is estimated that more than half of adolescents with ventricular pre-excitation are asymptomatic. 2, 10 Catheter ablation seems to be effective at eliminating the risk of sudden cardiac death in patients with ventricular preexcitation, and it has become widely available as a treatment modality for children for the last 15 years. However, ablation itself carries risk of adverse events (particularly atrioventricular [AV] block), and it is costly. Because increasing numbers of patients have been identified with asymptomatic pre-excitation, pediatric electrophysiologists have sought to develop an evidence-based approach to risk stratification appropriate for these patients. This need resulted in the recent publication of the 2012 PACES/HRS Guidelines on the Management of Asymptomatic Children with Ventricular Preexcitation. 11 These recommendations are based on the primary importance of defining the refractoriness of the accessory pathway. To do this, noninvasive exercise testing is proposed by the guidelines as a reasonable starting point. The abrupt loss of pre-excitation at high physiological heart rates seems to identify patients with longer accessory pathway refractory periods, and who can therefore be followed clinically. Unfortunately, <20% of children demonstrate this finding, 12 and invasive EP evaluation is recommended for the remainder to evaluate the properties of the accessory pathway directly.
The problem is this: once it has been decided to study a patient invasively, what is the best way to assess their specific risk, and which patients should undergo concomitant ablation? Kubuš and colleagues 13 from Prague and Leipzig have examined for the first time in the accompanying report the consequences of following the published guidelines. They have retrospectively evaluated the electrophysiological profile of 85 asymptomatic children (median age ≈15 years) with a ventricular pre-excitation pattern on their ECG, to assess the outcomes of invasive risk stratification applying current guidelines. All of the patients within the study had exhibited persistent pre-excitation up to the maximum achieved heart rate during an exercise stress test. Invasive EP testing was performed under either conscious sedation or general anesthesia. In the absence of high-risk pathway parameters (shortest pre-excited RR interval [SPERRI]≤250 ms or inducible atrio-ventricular reciprocating tachycardia [AVRT]) at baseline, isoproterenol either as repetitive boluses or a continuous infusion was given to increase the heart rate≥50%. At baseline, nearly 40% of patients had either rapid antegrade conduction or inducible AVRT, considered to be electrophysiological markers of risk and an indication for ablation. Forty-four patients went on to receive isoproterenol, causing an additional 15 (34%) subjects to have evidence of a rapid pathway and 4 (9%) subjects to have inducible SVT. The increased number of patients demonstrating either inducible SVT or evidence of a robust accessory pathway under catecholaminergic challenge to demonstrate more rapid conduction is consistent with the literature 14, 15 and reflects a phenomenon first reported by Wellens et al 16 
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April 2014 demonstrated that the administration of isoproterenol during testing of an accessory pathway in this type of patient reduces the measured effective refractory period and the shortest preexcited interval by 70 to 90 ms. 17 Thus, the use of isoproterenol markedly increases the prevalence of positive assignment of patients to a high-risk category. Conversely, the effects of anesthetic agents on the electrophysiology of the heart have been extensively documented, and although of lesser magnitude may have similar capacity to affect the measurements that we use to determine indications for ablation in these patients. 18, 19 It is significant to note that the historical studies from which specific values of atrial refractoriness are derived do not specify the use of catecholaminergic agents or techniques of sedation or anesthesia in those determinations. It seems logical and to some extent inherently obvious that sympathetic input into a patient with atrial fibrillation and manifest pre-excitation should enhance accessory pathway conduction exposing the patient to a higher likelihood of atrial fibrillation becoming more rapid and degenerating to ventricular fibrillation. Isoproterenol use in the EP laboratory may therefore be considered a means to counterbalance the effects of sedation and anesthesia and to more accurately represent physiological conditions during moments of stress or exertion. It may also be used to enhance nodal and VA conduction such that a patient without inducible AV reciprocating tachycardia at baseline is rendered inducible. Although this may be important and useful information, what it effectively means is that a choice by the physician made at the time of the invasive EP study procedure is highly likely to determine the outcome of the study. In this study, the use of isoproterenol nearly doubled the number of patients with high risk antegrade conduction properties. If one combines Class IIA (SPERRI<250 ms) with Class IIB (inducible AVRT) guidelines, that number nearly doubles again, with an additional 36% of patients in this study achieving criteria to move forward with a catheter ablation. In other words, depending on an operator's interpretation of the guidelines an ad hoc decision whether to test with or without the sensitizing agent isoproterenol and which criteria to use for recommending an ablation, the number of patients with an indication for ablation could vary by a factor of 3.
What findings might counterbalance an indication for ablation in a patient who has been deemed to be electrophysiologically high risk? Although ablation would seem to be indicated in the great majority of patients reported in Kubuš' article, catheter ablation was actually performed in only ≈70% of patients. 13 It was deferred in ≈15% of subjects with an adverse pathway secondary to a perinodal location. The authors have in this way explicitly identified a valuable additional concept in the risk assessment of these patients, one that is only clearly definable with EP study. That is: in addition to assessing the electrophysiological risk of an accessory pathway and its proclivity to cause cardiac arrest, one must also characterize the counterbalancing risk of ablation. This includes specific anatomic risks associated with pathway location adjacency to AV node or coronary sinus ostium, but may also be simply a function of patient size.
The patients who had ablation deferred in this group seem to be doing well, but it is important to note that the size of this group and the duration of follow-up are much less than would be necessary to determine prevalence of the relevant clinical outcome of cardiac arrest. Additional long-term natural history studies of asymptomatic children with isolated ventricular pre-excitation are likely to be impractical in the modern ablation era. It remains important to ascertain outcomes carefully, both in those patients who are ablated and those who did not undergo an ablation, whether by family choice, identification of a safe pathway or because of an anatomically adverse pathway location. The threshold adopted by the 2012 PACES/ HRS Guidelines for definition of high risk is a refractory period of 250 ms, a number which is so broadly accepted by consensus in the field that it has taken on something of a magical, Zen-like quality in this field and as a mantra is unlikely to be challenged by future outcomes-based data. Nonetheless, given the clear and predictable effect of study conditions on individual patients, and particularly the effect of isoproterenol to significantly reduce accessory pathway refractoriness, it may be worth considering how that threshold might be refined and interpreted. For instance, use of a threshold value for fastest manifest conduction of <220 ms under conditions of isoproterenol infusion may be more appropriate and consistent with earlier historical studies that showed children who were resuscitated from a life-threatening event or syncope, had an accessory pathway that performed <220 ms. 1, 3, 7, 20 "There are things known and there are things unknown, and in between these are doors of perception" (Aldous Huxley). The publication of guidelines instructing us how to manage children and adolescents with asymptomatic ventricular pre-excitation is indeed a Brave New World, one where one of our most difficult management problems has been reduced to an easily followed algorithm. But where evidence is lacking, decision must still be made, and guidelines such as those promulgated by our writing group in 2012 are in part based on consensus opinion. There is much we still do not know. We do not know how best to translate the results of EP testing, performed at one point in time, into a clear definition of risk, which may indicate that ablation may or may not be a desirable intervention. We have limited knowledge of the stability of the measurements we make from test to test, and how they vary with time and developmental stage. We do not fully understand the significance of intermittent pre-excitation. It is unclear how the risk of sudden death may vary with age, and the available literature on incidence of potentially lethal cardiac arrhythmias in asymptomatic ventricular pre-excitation and associated risk factors is incomplete, and not entirely consistent. Although we know that isoproterenol shortens the refractory period of the accessory pathway in a predictable manner, no study has conclusively shown that more ominous electrophysiological parameters on measured isoproterenol are associated with an increased risk of death.
Despite these uncertainties, we must try to achieve a balance between application of a catheter-based procedure with excellent success rates and low procedural risk versus a condition with little but not zero-risk of a life-threatening arrhythmia. 21, 22 Achieving that balance can be difficult, and the current work of Kubuš et al 13 highlights some of the practical issues that we now must address. During the past 15 years, catheter ablation has altered the natural history of the asymptomatic child with isolated ventricular pre-excitation, whose only risk factor for a life-threatening arrhythmia was a measurement of antegrade conduction obtained on isoproterenol. Consider the following clinical situation: a teenage soccer player has pre-excitation discovered on a screening ECG, and this persists during exercise testing. Her parents are concerned because of publicity surrounding a child in a neighboring community (who was known to have congenital heart disease) recently had a cardiac arrest during a gym class and died. In the EP laboratory, the patient is discovered to have an anteroseptal pathway in close proximity to the bundle of His. The fastest pre-excited RR interval at baseline is 310 ms, but this decreases to 240 ms during isoproterenol infusion. No SVT is induced. Should this patient undergo ablation? If an attempt is made and it fails, or if pre-excitation recurs, is a more aggressive second attempt warranted? If at the end of the day, the patient is pre-excited, should she therefore be excluded from participation in sports? What should the family be told? The significance of the decisions made by the clinician in the EP laboratory has a direct effect on the outcome, to study under sedation or general anesthesia, to use isoproterenol or not, to choose 220 ms as a threshold for risk assignment or 250 ms or some other value, to defer ablation in those patients with septal pathways, or in the ostium of the coronary sinus, or if the patient is below a certain weight. These types of uncertain choices must be considered explicitly and ideally should be discussed before EP studies for risk stratification and ablation between the patient, family, and physician. At the same time, we are challenged as a specialty to be more aware and attentive than ever in supervising and reporting the clinical outcomes in patients identified with ventricular pre-excitation, including those managed both with and without ablation, and in cases which adhere to or deviate from the 2012 PACES/HRS Guidelines. In this way, we will refine our understanding of these unresolved issues and where possible come to evidencebased consensus on the best management of these patients.
